Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Neogambogic acid

😃Good
Catalog No. T5724Cas No. 93772-31-7
Alias neo-gambogic acid

Neogambogic acid, an active ingredient in garcinia, can inhibit the growth of some solid tumors [resulting in an anticancer effect], and may be responsible for the inhibition of proliferation of human breast cancer cell line MCF-7 cells.

Neogambogic acid

Neogambogic acid

😃Good
Purity: 99.38%
Catalog No. T5724Alias neo-gambogic acidCas No. 93772-31-7
Neogambogic acid, an active ingredient in garcinia, can inhibit the growth of some solid tumors [resulting in an anticancer effect], and may be responsible for the inhibition of proliferation of human breast cancer cell line MCF-7 cells.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$240In Stock-
5 mg$600In Stock-
10 mg$840In Stock-
25 mg$1,500In Stock-
50 mg$2,100InquiryInquiry
100 mg$2,940InquiryInquiry
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.38%
Color:Yellow to Orange
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Neogambogic acid, an active ingredient in garcinia, can inhibit the growth of some solid tumors [resulting in an anticancer effect], and may be responsible for the inhibition of proliferation of human breast cancer cell line MCF-7 cells.
In vitro
Neo-gambogic acid(NGA) significantly reduced the proliferation of MCF-7 cells in a dose-dependent manner. NGA could increase the expression of the apoptosis-related proteins FasL, caspase-3, caspase-8, caspase-9, and Bax and decrease the expression of anti-apoptotic protein Bcl-2 accompanied by the mitochondrial transmembrane damage. The antiproliferative effect of NGA on MCF-7 cells is due to the G(0)/G(1) arrest, increased apoptosis and activation of Fas/FasL and cytochrome C pathway[1].
In vivo
Neo-gambogic acid(NGA) dose of ≤0.4 μg/ml had no significant effect on the proliferation of mouse BMMs in vitro (P>0.05);?concentrations of between 0.1-0.4 μg/ml significantly inhibited RANKL-induced osteoclastogenesis (P<0.01) in a dose-dependent manner.?Compared with the control group, NGA significantly reduced RANKL-induced bone resorption in vitro (P <0.01), and downregulated the expression of osteoclast-related mRNAs of TRAP, CTR, CTSK, and NFATc1.?NGA suppressed the activation of JNK but not the p38 signaling pathway and significantly reduced NF-κB p65 phosphorylation and the nuclear transport of NF-κB molecules, which inhibited NFATc1 expression.?CONCLUSIONS NGA suppressed RANKL-induced osteoclastogenesis by inhibiting the JNK and NF-κB pathways in mouse BMMs in vitro and reduced osteoclastic bone resorption[2].
Cell Research
MCF-7 cells (5* 10^4 ) were seeded into 96-well plates.Four hours later, 10 ul NGA in DMSO was added into the wells at various concentrations (0.5-24 ug/ml) and 0.1% DMSO was set as a negative control.?After 72 h, 50 ul MTT was added and cells were incubated for another 4 h. Then, media was removed and 150 ul DMSO was added and the plates were placed on a shaking table at 150 rpm for 10 min. Optical density (OD) was measured at 490 nm.?The experiment was repeated thrice and the rate of cell inhibition was calculated using the following formula: inhibition rate [1-(OD test/ OD negative control)]*100%[1].
Animal Research
Primary mouse BMMs were cultured with increasing concentrations of NGA.?Real-time polymerase chain reaction was used to study the expression of mRNAs corresponding to gene products specific to receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation, including tartrate-resistant acid phosphatase (TRAP), calcitonin receptor (CTR), cathepsin K (CTSK), and nuclear factor of activated T cells c1 (NFATc1).?A cell counting kit-8 assay was used to evaluate cell proliferation.?Western blotting and confocal immunofluorescence microscopy were used to investigate the signaling pathways.?A bone resorption model was used to quantify bone resorption[2].
Synonymsneo-gambogic acid
Chemical Properties
Molecular Weight646.77
FormulaC38H46O9
Cas No.93772-31-7
SmilesC(/C=C(\C(O)=O)/C)[C@@]12[C@]34C(C(=O)C=5C(O3)=C(CC=C(C)C)C6=C(C5O)C(O)C[C@](CCC=C(C)C)(C)O6)=CC(C1=O)(C[C@]4(C(C)(C)O2)[H])[H]
Relative Density.1.32 g/cm3
Storage & Solubility Information
Storagekeep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 6.47 mg/mL (10 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.5461 mL7.7307 mL15.4614 mL77.3072 mL
5 mM0.3092 mL1.5461 mL3.0923 mL15.4614 mL
10 mM0.1546 mL0.7731 mL1.5461 mL7.7307 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Neogambogic acid | purchase Neogambogic acid | Neogambogic acid cost | order Neogambogic acid | Neogambogic acid chemical structure | Neogambogic acid in vivo | Neogambogic acid in vitro | Neogambogic acid formula | Neogambogic acid molecular weight